What's the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC carries a Drug Affinity Complex, a modification that binds circulating albumin and extends how long the peptide stays active. CJC-1295 without DAC — often labeled Mod GRF 1-29 — lacks that modification and clears the body much faster, which is why research protocols built around it call for dosing it more frequently.

Does the reconstitution math change between the two forms?

No. Concentration equals vial mass divided by water volume, and syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe, for either form. The DAC modification changes how long the compound stays active — it does not change the reconstitution arithmetic.

Why is CJC-1295 without DAC sometimes labeled Mod GRF 1-29?

Mod GRF 1-29 refers to the same modified GHRH fragment sold as CJC-1295 without DAC — the two names describe the same molecule. Vendors use either term, so check the supplier's product description if the labeling on a specific vial is unclear.

Can one calculator handle both forms of CJC-1295?

Yes. The calculator's formula works from vial mass, water volume, and target dose — inputs that don't reference DAC status. Enter the numbers printed on whichever vial you have, with-DAC or without, and the syringe-unit math is the same.

CJC-1295 No DAC vs With DAC Calculator

By PeptCalc Research — Medically reviewed by David Mansour, MD — Last reviewed July 20, 2026

CJC-1295 shows up on vendor labels in two distinct chemical forms — with DAC and without DAC — and mixing up which one is in a given vial changes more than the wording on the label. This reference compares CJC-1295 no DAC vs with DAC: what separates the two forms, how a reconstitution calculator handles each, and where a research protocol built around one form does not carry over to the other. It is written for research and educational purposes only and is not medical advice.

What separates CJC-1295 with DAC and without DAC

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), and both forms act on the same GHRH receptor. The difference between them is structural, not a matter of potency. CJC-1295 with DAC carries a Drug Affinity Complex, a chemical modification that lets the peptide bind circulating albumin — the mechanism behind why it stays active in the body far longer than the unmodified peptide. CJC-1295 without DAC — commonly labeled Mod GRF 1-29 on vendor sites — lacks that modification. It clears the body much faster, and research protocols built around it call for dosing it considerably more often, sometimes more than once in a single day, to keep pace with its shorter window of activity.

A vial simply labeled "CJC-1295," with no DAC status stated, is genuinely ambiguous. The reconstitution math will still work, but any research dosing frequency drawn from the literature depends entirely on knowing which form is actually in the vial. Check the label or the certificate of analysis before assuming either one.

Regulatory and research status

Neither form of CJC-1295 has an FDA-approved pharmaceutical formulation for human use. Both remain research compounds studied in preclinical and limited early human research rather than approved therapeutics. This article covers the underlying chemistry and reconstitution arithmetic for each form — not a use recommendation.

Vial formats and typical concentrations

Format	Description
CJC-1295 with DAC	Sold as a standalone vial, typically 2 mg or 5 mg of lyophilized peptide. The label or COA should state "with DAC" or "DAC" explicitly.
CJC-1295 without DAC (Mod GRF 1-29)	Sold as a standalone vial, typically 2 mg or 5 mg, or pre-blended with Ipamorelin. Vendors may use either name on the label.

Both forms reconstitute the same way: lyophilized peptide plus bacteriostatic water, mixed to whatever concentration the researcher chooses. DAC status does not change the reconstitution formula — only the research-cited dosing frequency differs between the two. The peptide calculator works out concentration and syringe units for either vial from the same three inputs.

Worked example: same formula, two different molecules

Concentration equals vial mass divided by water volume. Syringe units equal that volume in mL multiplied by 100 on a U-100 insulin syringe. Neither equation changes based on which form of CJC-1295 is in the vial.

CJC-1295 with DAC. A 2 mg vial with 2 mL of bacteriostatic water is 1 mg/mL. A 0.3 mg dose is 0.3 ÷ 1 = 0.3 mL, or 0.3 × 100 = 30 units.

CJC-1295 without DAC (Mod GRF 1-29). A 5 mg vial with 2 mL of bacteriostatic water is 2.5 mg/mL. A 0.1 mg dose is 0.1 ÷ 2.5 = 0.04 mL, or 0.04 × 100 = 4 units.

Same formula, two different vials, two very different unit readings — because the vial size and water volume set the concentration, not the DAC modification.

Why one calculator covers both

Here's how we see it: the point where a research dose actually goes wrong is the reconstitution step, not the injection. A U-100 insulin syringe measures a fixed 100 units per mL no matter what is dissolved in the vial, so the mg-per-unit depends entirely on how much water went in — true whether the vial holds CJC-1295 with DAC, without DAC, or an unrelated compound entirely. That's why the same mass-divided-by-volume formula, run through the peptide reconstitution calculator, handles both forms without any adjustment for DAC status. For the general mixing steps, see how to reconstitute peptides.

Where the comparison breaks down

The reconstitution math is identical; the research protocols are not. Because the DAC modification is what extends how long CJC-1295 remains active, a dosing frequency referenced for the no-DAC form does not transfer to the DAC form, and the reverse is equally true. Treating "CJC-1295" as a single compound with a single protocol, without first checking DAC status, is the most common mix-up in how this pair gets discussed. The CJC-1295 & Ipamorelin dosage calculator guide covers the blend format specifically, which most often pairs Ipamorelin with the no-DAC form rather than the DAC form.

Common mistakes

Assuming an unlabeled vial is one form or the other. "CJC-1295" alone is ambiguous. Confirm DAC status from the label or COA before applying any dosing reference to it.
Carrying a dosing frequency from one form over to the other. The DAC modification is specifically what changes how the compound is referenced in research protocols — a no-DAC frequency says nothing about the DAC form's, and vice versa.
Confusing mg and mcg. CJC-1295 doses are described in milligrams or micrograms depending on the supplier. 1 mg equals 1,000 mcg, and reading one for the other produces a 1,000x error.
Shaking the vial. Swirl gently instead — shaking can degrade the peptide.
Assuming a blend vial is always the no-DAC form. It usually is, since Ipamorelin's short action window pairs more naturally with the no-DAC form than with DAC's extended activity, but confirm on the specific label rather than assuming.

For the blend-vial math specifically, see the CJC-1295 & Ipamorelin dosage calculator guide. For general mixing steps, see how to reconstitute peptides. Or enter your own vial size, water volume, and target dose into the free peptide calculator to see the exact syringe units for either form of CJC-1295.